Thibaud Soumagne1, Pierantonio Laveneziana2, Matthieu Veil-Picard1, Alicia Guillien3, Frédéric Claudé1, Marc Puyraveau4, Isabella Annesi-Maesano5, Nicolas Roche6, Jean-Charles Dalphin7, Bruno Degano3. 1. Service de Physiologie-Explorations Fonctionnelles, Besançon, France Service de Pneumologie, Besançon, France. 2. Sorbonne Universités, INSERM, UMR_S 1158, Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service des Explorations Fonctionnelles de la Respiration, de l'Exercice et de la Dyspnée, Paris, France. 3. Service de Physiologie-Explorations Fonctionnelles, Besançon, France EA 3920, Université de Franche-Comté, Besançon, France. 4. Centre de Méthodologie Clinique, CHU Besançon, Besançon, France. 5. Epidémiologie des Maladies Respiratoires et Allergiques i-PLESP INSERM et UPMC, Paris, France. 6. Service de Pneumologie et Soins Intensifs Respiratoires, Groupe Hospitalier Cochin, Site Val de Grâce, AP-HP et Université Paris Descartes (EA2511), Sorbonne-Paris-Cité, Paris, France. 7. Service de Pneumologie, Besançon, France UMR CNRS Chrono Environnement, Université de Franche-Comté, Besançon, France.
Abstract
BACKGROUND: The relevance of screening for airway obstruction in subjects not complaining of COPD symptoms may depend on the definition of airway obstruction. Response to exercise in asymptomatic subjects with persistent airway obstruction as defined by a postbronchodilator FEV1/FVC <5th centile lower limit of normal (LLN) remains unknown. METHODS: Dyspnoea (Borg scale), exercise tolerance and ventilatory constraints on tidal volume expansion were assessed in 20 consecutive asymptomatic subjects with persistent mild airway obstruction detected by screening (postbronchodilator FEV1/FVC z-score: -2.14±0.29; FEV1 z-score: -1.02±0.64) undergoing incremental cycle cardiopulmonary exercise testing, compared with 20 healthy controls with normal spirometry matched for age, sex, body mass index and smoking history (FEV1/FVC z-score: -0.13±0.57; FEV1 z-score: 0.32±0.67) and with 20 symptomatic patients with COPD matched for the same characteristics (FEV1/FVC z-score: -2.36±0.51; FEV1 z-score: -1.02±0.48). RESULTS: Asymptomatic subjects with airway obstruction had higher dyspnoea ratings than controls during incremental exercise. Asymptomatic subjects with airway obstruction had also peak oxygen consumption and peak power output that were lower than controls, and similar to those observed in patients with COPD. Although less frequent than in COPD, dynamic hyperinflation was more frequent in asymptomatic subjects with airway obstruction than in controls (85%, 50% and 10%, respectively; p=0.01 in asymptomatic subjects vs controls and p=0.04 vs COPD). CONCLUSIONS: Although they did not present with chronic activity-related dyspnoea, subjects with a postbronchodilator FEV1/FVC<LLN as detected by screening had poorer exercise tolerance than healthy controls on exertion, and a significant proportion of them had dynamic hyperinflation. These subjects may, therefore, deserve further attention and may warrant regular follow-up. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: The relevance of screening for airway obstruction in subjects not complaining of COPD symptoms may depend on the definition of airway obstruction. Response to exercise in asymptomatic subjects with persistent airway obstruction as defined by a postbronchodilator FEV1/FVC <5th centile lower limit of normal (LLN) remains unknown. METHODS:Dyspnoea (Borg scale), exercise tolerance and ventilatory constraints on tidal volume expansion were assessed in 20 consecutive asymptomatic subjects with persistent mild airway obstruction detected by screening (postbronchodilator FEV1/FVC z-score: -2.14±0.29; FEV1 z-score: -1.02±0.64) undergoing incremental cycle cardiopulmonary exercise testing, compared with 20 healthy controls with normal spirometry matched for age, sex, body mass index and smoking history (FEV1/FVC z-score: -0.13±0.57; FEV1 z-score: 0.32±0.67) and with 20 symptomatic patients with COPD matched for the same characteristics (FEV1/FVC z-score: -2.36±0.51; FEV1 z-score: -1.02±0.48). RESULTS: Asymptomatic subjects with airway obstruction had higher dyspnoea ratings than controls during incremental exercise. Asymptomatic subjects with airway obstruction had also peak oxygen consumption and peak power output that were lower than controls, and similar to those observed in patients with COPD. Although less frequent than in COPD, dynamic hyperinflation was more frequent in asymptomatic subjects with airway obstruction than in controls (85%, 50% and 10%, respectively; p=0.01 in asymptomatic subjects vs controls and p=0.04 vs COPD). CONCLUSIONS: Although they did not present with chronic activity-related dyspnoea, subjects with a postbronchodilator FEV1/FVC<LLN as detected by screening had poorer exercise tolerance than healthy controls on exertion, and a significant proportion of them had dynamic hyperinflation. These subjects may, therefore, deserve further attention and may warrant regular follow-up. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Praful Schroff; Jason Hitchcock; Christopher Schumann; J Michael Wells; Mark T Dransfield; Surya P Bhatt Journal: Ann Am Thorac Soc Date: 2017-01
Authors: Sotirios Kakavas; Ourania S Kotsiou; Fotis Perlikos; Maria Mermiri; Georgios Mavrovounis; Konstantinos Gourgoulianis; Ioannis Pantazopoulos Journal: NPJ Prim Care Respir Med Date: 2021-05-07 Impact factor: 2.871
Authors: Gonzalo Labarca; Andrea Bustamante; Gonzalo Valdivia; Rodrigo Díaz; Álvaro Huete; Paul Mac Nab; Laura Mendoza; Jaime Leppe; Carmen Lisboa; Fernando Saldías; Orlando Díaz Journal: BMJ Open Date: 2017-08-11 Impact factor: 2.692
Authors: Thibaud Soumagne; Marie-Laure Chardon; Gaël Dournes; Lucie Laurent; Bruno Degano; François Laurent; Jean Charles Dalphin Journal: PLoS One Date: 2017-06-14 Impact factor: 3.240
Authors: Frits M E Franssen; Dionne E Smid; Dorly J H Deeg; Martijn Huisman; Jan Poppelaars; Emiel F M Wouters; Martijn A Spruit Journal: NPJ Prim Care Respir Med Date: 2018-08-10 Impact factor: 2.871
Authors: Jacob Sandberg; Magnus Ekström; Mats Börjesson; Göran Bergström; Annika Rosengren; Oskar Angerås; Kjell Toren Journal: BMJ Open Respir Res Date: 2020-09